Urso 250 and Remicade drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Urso 250 (ursodiol) and Remicade (infliximab). Common drug interactions include bladder cancer among females and cytomegalovirus infection among males.

The phase IV clinical study analyzes what interactions people have when they take Urso 250 and Remicade. It is created by eHealthMe based on reports of 72 people who take the same drugs from the FDA, and is updated regularly.

What is Urso 250?

Urso 250 has active ingredients of ursodiol. eHealthMe is studying from 5,080 Urso 250 users. Check the latest studies of Urso 250.

What is Remicade?

Remicade has active ingredients of infliximab. It is often used in crohn's disease. eHealthMe is studying from 224,011 Remicade users. Check the latest studies of Remicade.



On Jul, 12, 2026

72 people who take Urso 250 and Remicade together, and have interactions are studied.

Urso 250 and Remicade drug interactions.

What are the common drug interactions of Urso 250 and Remicade, by gender? *:

female:

  1. Bladder cancer
  2. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
  3. Fungal infection
  4. Death
  5. Gingivitis (inflammation of gums)
  6. Pneumocystis jiroveci infection (fungal infection of the lungs)
  7. Pneumonia cytomegaloviral (cmv pneumonia is caused by a member of a group of herpes-type viruses)
  8. Bacteraemia (presence of bacteria in the blood)
  9. Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters)
  10. Encephalopathy (functioning of the brain is affected by some agent or condition)

male:

  1. Cytomegalovirus infection
  2. Pancreatitis acute (sudden inflammation of pancreas)
  3. Disseminated intravascular coagulation (systemic activation of blood coagulation)
  4. Fistula (an abnormal connection or passageway between two)
  5. Ileal stenosis (obstruction in the ileal)
  6. Pneumonia cryptococcal (pneumonia caused by cryptococcal infection)
  7. Pseudomonas infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa)
  8. Renal impairment (severely reduced kidney function)
  9. Altered state of consciousness (altered state of mind)
  10. C-reactive protein increased

What are the common drug interactions of Urso 250 and Remicade, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Blood creatine phosphokinase increased
  2. Iron deficiency anaemia
  3. Lymphocyte stimulation test positive
  4. Myalgia (muscle pain)
  5. Pancreatitis acute (sudden inflammation of pancreas)
  6. Pneumonia
  7. Bacteraemia (presence of bacteria in the blood)
  8. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
  9. Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters)
  10. Encephalopathy (functioning of the brain is affected by some agent or condition)

20-29:

  1. Cholangitis sclerosing (infection and obstruction of bile duct)
  2. Clostridial infection (infectious conditions by clostridium bacteria)

30-39:

  1. Cytomegalovirus infection
  2. Fistula (an abnormal connection or passageway between two)
  3. Ileal stenosis (obstruction in the ileal)
  4. Pneumonia cryptococcal (pneumonia caused by cryptococcal infection)
  5. Pseudomonas infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa)
  6. Blindness
  7. Coma (state of unconsciousness lasting more than six hours)
  8. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
  9. Drug ineffective
  10. Furuncle (infection of the hair follicle)

40-49:

  1. Pneumocystis jiroveci pneumonia (fungal infection of the lungs)
  2. Pyrexia (fever)
  3. Renal disorder (kidney disease)
  4. Liver disorder (liver diseases)
  5. Drug-induced liver injury (diseases of the liver that are caused by physician-prescribed medications)
  6. Acute graft versus host disease (acute complication following an allogeneic tissue/blood transplant)
  7. Acute respiratory failure
  8. Circulatory collapse
  9. Cytomegalovirus infection
  10. Encephalitis herpes (inflammation of the brain due to herpes infection)

50-59:

  1. Pancreatitis acute (sudden inflammation of pancreas)
  2. Hepatosplenic t-cell lymphoma (neoplasm comprising medium-sized cytotoxic t-cells that show a significant sinusoidal infiltration in the liver, spleen, and bone marrow)
  3. Dysphagia (a condition in which swallowing is difficult or painful)
  4. Cardiomegaly (increased size of heart than normal)
  5. Pericardial effusion (fluid around the heart)
  6. Altered state of consciousness (altered state of mind)
  7. C-reactive protein increased
  8. Central nervous system lesion (an abnormality in tissue of brain or spinal cord)
  9. Disease progression
  10. Lymphocyte count decreased

60+:

  1. Ascites (accumulation of fluid in the abdominal cavity)
  2. Peritoneal tuberculosis
  3. Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)
  4. Bladder cancer
  5. Blood pressure decreased
  6. Depressed level of consciousness
  7. Fungal infection
  8. Hypoxia (low oxygen in tissues)
  9. Infusion related reaction
  10. Death

What are the existing conditions these people have? *

  1. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 24 people, 33.33%
  2. Osteoporosis (bones weak and more likely to break): 14 people, 19.44%
  3. High Blood Pressure: 11 people, 15.28%
  4. Hepatic Function Abnormal: 11 people, 15.28%
  5. Psoriasis (immune-mediated disease that affects the skin): 10 people, 13.89%
  6. Insomnia (sleeplessness): 10 people, 13.89%
  7. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 9 people, 12.50%
  8. Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 8 people, 11.11%
  9. Gastritis (inflammation of stomach): 8 people, 11.11%
  10. Reflux Oesophagitis (an oesophageal mucosal injury that occurs of gastric contents into the oesophagus): 7 people, 9.72%

* Approximation only. Some reports may have incomplete information.

Do you take Urso 250 and Remicade?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Urso 250 and Remicade:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Urso 250:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Remicade:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Urso 250 and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Remicade and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ursodiol and infliximab (the active ingredients of Urso 250 and Remicade, respectively), and Urso 250 and Remicade (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: